Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 945769, 8 pages
http://dx.doi.org/10.1155/2015/945769
Research Article

Risk Factors and Scoring System for Predicting Bacterial Resistance to Cefepime as Used Empirically in Haematology Wards

1Assistance Publique-Hôpitaux de Paris (APHP), Haematology Department, Henri Mondor Hospital and Paris-Est-Créteil University, 94000 Créteil, France
2Haematology Department, Hôpital Militaire d’Instruction Mohamed V, Rabat, Morocco
3Microbiology Laboratory, Henri Mondor Hospital, 94000 Créteil, France
4Equipe ATIP/AVENIR, INSERM, UMR 738, 75018 Paris, France
5University Paris Diderot, Sorbonne Paris Cité, UMR 738, 75018 Paris, France

Received 24 January 2015; Accepted 4 April 2015

Academic Editor: Kurt G. Naber

Copyright © 2015 Hicham El Maaroufi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. G. Freifeld, E. J. Bow, K. A. Sepkowitz et al., “Clinical practice guidelines for the use of antiicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America,” Clinical Infectious Diseases, vol. 52, no. 4, pp. e56–e93, 2011. View at Google Scholar
  2. D. Caselli, S. Cesaro, E. Castagnola, and M. Aricò, “Multidrug resistant Pseudomonas aeruginosa bloodstream infection: comparison between children and adult patients with cancer (reply),” Haematologica, vol. 96, no. 1, article e4, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Gudiol, L. Calatayud, C. Garcia-Vidal et al., “Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome,” The Journal of Antimicrobial Chemotherapy, vol. 65, no. 2, pp. 333–341, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Mikulska, V. del Bono, A. M. Raiola et al., “Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of gram-negative rods and increasing antibiotic resistance,” Biology of Blood and Marrow Transplantation, vol. 15, no. 1, pp. 47–53, 2009. View at Publisher · View at Google Scholar
  5. M. Mikulska, C. Viscoli, C. Orasch et al., “Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients,” Journal of Infection, vol. 68, no. 4, pp. 321–331, 2014. View at Publisher · View at Google Scholar
  6. E. Trecarichi, L. Pagano, A. Candoni et al., “Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey,” Clinical Microbiology and Infection, 2014. View at Publisher · View at Google Scholar
  7. E. M. Trecarichi, M. Tumbarello, T. Spanu et al., “Incidence and clinical impact of extended-spectrum-betalactamase production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies,” Journal of Infection, vol. 58, no. 4, pp. 299–307, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Tumbarello, M. Sali, E. M. Trecarichi et al., “Bloodstream infections caused by extended-spectrum-β-lactamase-producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 9, pp. 3244–3252, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Averbuch, C. Orasch, C. Cordonnier et al., “European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia,” Haematologica, vol. 98, no. 12, pp. 1826–1835, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Courpon-Claudinon, A. Lefort, X. Panhard et al., “Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features,” Clinical Microbiology and Infection, vol. 17, no. 4, pp. 557–565, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Oteo, M. Perez-Vazquez, and J. Campos, “Extended-spectrum β-lactamase producing Escherichia coli: changing epidemiology and clinical impact,” Current Opinion in Infectious Diseases, vol. 23, no. 4, pp. 320–326, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Vernaz, B. Huttner, D. Muscionico et al., “Modelling the impact of antibiotic use on antibiotic-resistant Escherichia coli using population-based data from a large hospital and its surrounding community,” Journal of Antimicrobial Chemotherapy, vol. 66, no. 4, pp. 928–935, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. K. M. Wener, V. Schechner, H. S. Gold, S. B. Wright, and Y. Carmeli, “Treatment with fluoroquinolones or with β-lactam-β-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-β-lactamase-producing klebsiella species in hospitalized patients,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 5, pp. 2010–2016, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Caselli, S. Cesaro, O. Ziino et al., “Multidrug resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation,” Haematologica, vol. 95, no. 9, pp. 1612–1615, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Hummel, C. Warga, H. Hof, R. Hehlmann, and D. Buchheidt, “Diagnostic yield of blood cultures from antibiotic-nave and antibiotically treated patients with haematological malignancies and high-risk neutropenia,” Scandinavian Journal of Infectious Diseases, vol. 41, no. 9, pp. 650–655, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. C.-I. Kang, D. R. Chung, K. S. Ko, K. R. Peck, and J.-H. Song, “Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy,” Annals of hematology, vol. 91, no. 1, pp. 115–121, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. C.-Y. Liu, Y.-C. Lai, L.-J. Huang et al., “Impact of bloodstream infections on outcome and the influence of prophylactic oral antibiotic regimens in allogeneic hematopoietic SCT recipients,” Bone Marrow Transplantation, vol. 46, no. 9, pp. 1231–1239, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. R. C. Bone, R. A. Balk, F. B. Cerra et al., “Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine,” Chest, vol. 101, no. 6, pp. 1644–1655, 1992. View at Google Scholar
  19. C. Cordonnier, R. Herbrecht, J. L. Pico et al., “Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study,” Clinical Infectious Diseases, vol. 24, no. 1, pp. 41–51, 1997. View at Publisher · View at Google Scholar · View at Scopus
  20. W. T. Hughes, D. Armstrong, G. P. Bodey et al., “2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer,” Clinical Infectious Diseases, vol. 34, no. 6, pp. 730–751, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Baron, M. Weinstein, W. Dunne Jr., D. Welch, and D. Wilson, Eds., Blood Cultures IV, American Society for Microbiology, Washington, DC, USA, 2005.
  22. L. Dortet, P. Legrand, C.-J. Soussy, and V. Cattoir, “Bacterial identification, clinical significance, and antimicrobial susceptibilities of Acinetobacter ursingii and Acinetobacter schindleri, two frequently misidentified opportunistic pathogens,” Journal of Clinical Microbiology, vol. 44, no. 12, pp. 4471–4478, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. “Recommandations du Comité de l'Antibiogramme de la Société Française de microbiologie,” 2012, http://www.sfm-microbiologie.org.
  24. V. Jarlier, M. H. Nicolas, G. Fournier, and A. Philippon, “Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns,” Reviews of Infectious Diseases, vol. 10, no. 4, pp. 867–878, 1988. View at Publisher · View at Google Scholar · View at Scopus
  25. E. W. Steyerberg, M. J. C. Eijkemans, and J. D. F. Habbema, “Stepwise selection in small data sets: a simulation study of bias in logistic regression analysis,” Journal of Clinical Epidemiology, vol. 52, no. 10, pp. 935–942, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. E. W. Steyerberg, F. E. Harrell Jr., G. J. J. M. Borsboom, M. J. C. Eijkemans, Y. Vergouwe, and J. D. F. Habbema, “Internal validation of predictive models: efficiency of some procedures for logistic regression analysis,” Journal of Clinical Epidemiology, vol. 54, no. 8, pp. 774–781, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Rodriguez-Bano, E. Picon, P. Gijon et al., “Communityonset bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: risk factors and prognosis,” Clinical Infectious Diseases, vol. 50, no. 1, pp. 40–48, 2010. View at Publisher · View at Google Scholar
  28. T. Chopra, D. Marchaim, J. Veltman et al., “Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli,” Antimicrobial Agents and Chemotherapy, vol. 56, no. 7, pp. 3936–3942, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. C. F. M. van der Donk, P. S. Beisser, J. A. A. Hoogkamp-Korstanje, C. A. Bruggeman, and E. E. Stobberingh, “A 12 year (1998–2009) antibiotic resistance surveillance of Klebsiella pneumoniae collected from intensive care and urology patients in 14 Dutch hospitals,” Journal of Antimicrobial Chemotherapy, vol. 66, no. 4, pp. 855–858, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Ariffin, P. Navaratnam, M. Mohamed et al., “Ceftazidime-resistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia,” International Journal of Infectious Diseases, vol. 4, no. 1, pp. 21–25, 2000. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Carlet, P. Collignon, D. Goldmann et al., “Society's failure to protect a precious resource: antibiotics,” The Lancet, vol. 378, no. 9788, pp. 369–371, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. J. M. Hughes, “Preserving the lifesaving power of antimicrobial agents,” Journal of the American Medical Association, vol. 305, no. 10, pp. 1027–1028, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Tumbarello, T. Spanu, M. Sanguinetti et al., “Bloodstream infections caused by extended-spectrum-β-lactamase- producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 2, pp. 498–504, 2006. View at Publisher · View at Google Scholar · View at Scopus